Skip to main content

Table 5 Clinical course of the gefitinib-responders who achieved PD, underwent chemotherapy, and rechallenged with gefitinib

From: Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

No. Chemotherapy regimen after failure of gefitinib Best response of the chemotherapy Response of gefitinib rechallenge Time to re-progression (month)
5 GEM+VNR PR PR 6.2
6 GEM+VNR PD SD 7.8
7 GEM+DTX SD PD 0.6
8 CBDCA+CPT-11 → AMR → S-1 SD SD 1.9+
9 DTX SD SD 4.3+
10 DTX SD NE 0.9+
  1. "Rechallenge" of gefitinib indicates restarting gefitinib after cessation of gefitinib followed by other chemotherapy. GEM, gemcitabine; VNR, vinorelbine; DTX, docetaxel; CBDCA, carboplatin; CPT-11, irinotecan; AMR, amrubicin; Time to re-progression, time to progression from the date of rechallenging gefitinib; +, still continuing the response at the last date of follow-up